Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunotherapy
Stallergenes SA details research in immunotherapy
December 10th, 2008
According to recent research published in the journal Clinical and Experimental Allergy, " Sublingual immunotherapy (SLIT) has been established in humans as a safe and efficacious treatment for type I respiratory allergies. Porphyromonas gingivalis In this study, we compared three Toll-like receptor (TLR) 2 ligands (Pam3CSK4, Porphyromonas gingivalis lipopolysaccharide and lipoteichoic acid) as potential adjuvants for sublingual allergy vaccines." " These molecules were tested in co-cultures of adjuvant-pre-treated dendritic cells (DCs) with murine naive CD4(+) T lymphocytes. Patterns of cytokine production, phenotype, proliferation and gene expression were...
Source: Vaccine Weekly (2008-12-10)
|
